BRIEF-Glaukos Announces Positive Topline Outcomes In Phase 3 Confirmatory Trial For Epioxa, Achieving Primary Efficacy Endpoint And Demonstrating Favorable Tolerability And Safety

Reuters10-17

Oct 16 (Reuters) - Glaukos Corp :

* GLAUKOS ANNOUNCES POSITIVE TOPLINE OUTCOMES IN PHASE 3 CONFIRMATORY TRIAL FOR EPIOXA™, ACHIEVING PRIMARY EFFICACY ENDPOINT AND DEMONSTRATING FAVORABLE TOLERABILITY AND SAFETY

* GLAUKOS CORP - PHASE 3 TRIAL SUPPORTS NDA SUBMISSION BY END OF 2024

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2476973990?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-17 04:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2476973990","market":"us","top_or_hot":-1,"title":"BRIEF-Glaukos Announces Positive Topline Outcomes In Phase 3 Confirmatory Trial For Epioxa, Achieving Primary Efficacy Endpoint And Demonstrating Favorable Tolerability And Safety","media":"Reuters","content":"<html><body><p>Oct 16 (Reuters) - <a href=\"https://laohu8.com/S/GKOS\">Glaukos Corp</a>   :</p><p>   * GLAUKOS ANNOUNCES POSITIVE TOPLINE OUTCOMES IN PHASE 3 CONFIRMATORY TRIAL FOR EPIOXA™, ACHIEVING PRIMARY EFFICACY ENDPOINT AND DEMONSTRATING FAVORABLE TOLERABILITY AND SAFETY</p><p>   * GLAUKOS CORP - PHASE 3 TRIAL SUPPORTS NDA SUBMISSION BY END OF 2024</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Glaukos Announces Positive Topline Outcomes In Phase 3 Confirmatory Trial For Epioxa, Achieving Primary Efficacy Endpoint And Demonstrating Favorable Tolerability And Safety</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Glaukos Announces Positive Topline Outcomes In Phase 3 Confirmatory Trial For Epioxa, Achieving Primary Efficacy Endpoint And Demonstrating Favorable Tolerability And Safety\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-17 04:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Oct 16 (Reuters) - Glaukos Corp   :   * GLAUKOS ANNOUNCES POSITIVE TOPLINE OUTCOMES IN PHASE 3 CONFIRMATORY TRIAL FOR EPIOXA™, ACHIEVING PRIMARY EFFICACY ENDPOINT AND DEMONSTRATING FAVORABLE ...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GKOS","symbol_name":"Glaukos Corp","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2476973990","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2476973990","pubTimestamp":1729109864,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"Oct 16  - Glaukos Corp   :   * GLAUKOS ANNOUNCES POSITIVE TOPLINE OUTCOMES IN PHASE 3 CONFIRMATORY TRIAL FOR EPIOXA, ACHIEVING PRIMARY EFFICACY ENDPOINT AND DEMONSTRATING FAVORABLE TOLERABILITY AND SAFETY   * GLAUKOS CORP - PHASE 3 TRIAL SUPPORTS NDA SUBMISSION BY END OF 2024Source text for Eikon:    Further company coverage:    ","collect":0,"end_time":0,"defaultTopTitle":"","property":["rate"],"viewcount":null,"language":"en","relate_stocks":{"GKOS":"Glaukos Corp"},"translate_title":"简介-Glaukos宣布Epioxa 3期验证性试验取得积极的顶线结果，达到主要疗效终点并证明了良好的耐受性和安全性","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GKOS":1},"content_text":"Oct 16 (Reuters) - Glaukos Corp   :   * GLAUKOS ANNOUNCES POSITIVE TOPLINE OUTCOMES IN PHASE 3 CONFIRMATORY TRIAL FOR EPIOXA™, ACHIEVING PRIMARY EFFICACY ENDPOINT AND DEMONSTRATING FAVORABLE TOLERABILITY AND SAFETY   * GLAUKOS CORP - PHASE 3 TRIAL SUPPORTS NDA SUBMISSION BY END OF 2024Source text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2476973990"}